
-
German biathlete confirmed dead after accident on Pakistan mountain
-
Marchand smashes long-standing 200m medley world record
-
US economy returns to growth in second quarter on tariff turbulence
-
'All gone': Beijing villagers left with nothing after deadly floods
-
Aston Martin pares outlook as US tariffs weigh
-
Adidas says may hike US prices after tariff cost warning
-
GSK reports improved outlook despite US drug tariffs
-
Olympic champ Pan crashes out again in second worlds flop
-
US, India launch powerful Earth-monitoring satellite
-
Thailand and Cambodia trade allegations of truce breaking
-
Thai family mourns soldier son killed just before truce
-
Zimbabwe's Taylor to return after corruption and drugs ban
-
'Whirlwind' as Australia's O'Callaghan romps to 200m world gold
-
Portugal gains control of some wildfires
-
Bayern Munich boost firepower with Diaz signing
-
Tunisia's Jaouadi wins 800m freestyle gold for first major title
-
Hermes confirms outlook for rising sales in 2025
-
Stocks diverge, dollar slips before tech earnings, Fed decision
-
Australian medal hope latest swimmer hit by tummy trouble at worlds
-
England captain Stokes out of India series decider
-
HSBC banks lower profits on higher costs
-
Shanghai police bust gang selling counterfeit Labubu toys
-
Eurozone economy expands but tariff impact looms
-
Shanghai evacuates 283,000 people as typhoon hits
-
Ryanair says dropping three French airports over 'harmful' tax
-
China says childcare subsidies to 'add new impetus' to economy
-
Mercedes-Benz welcomes EU-US deal after profits plunge on tariff woes
-
Bayern Munich sign Luis Diaz from Liverpool
-
Adidas reports hit from US tariffs
-
Italy opens probe into Meta over AI tool in WhatsApp
-
Russian TV shows buildings swept away as tsunami hits coast
-
Japan sees new record high temperature of 41.2C
-
Mercedes-Benz profit plunges on tariff, China woes
-
Climbers attempt rescue of German biathlete injured on Pakistan mountain
-
Life after cod: Latvia reinvents its coastal communities
-
Kyrgyzstan struggles with deadly shortages of medicine
-
Canada project reclaims 'foul' industrial area to contain floods
-
Toxic Balkan wildfires ignite in poorly managed dumps
-
Intimate no more? Japan clamps down on 'host clubs'
-
Could copper tariff hurt US more than Chile?
-
Marchand gears up for 200m IM world record bid
-
Thousands of carpets sunbathe at Turkish resort
-
'I didn't feel safe': Banned Canada coach explains move to New Zealand
-
Norwegian cousins battle over oil, climate policy
-
Zverev makes winning Toronto return after a month off court
-
Thailand accuses Cambodia of 'flagrant violation' of truce
-
'Marathon at F1 speed': China bids to lap US in AI leadership
-
Stablecoins inspire hope, and hype, in Hong Kong
-
Markets mixed as China-US talks end, eyes on tech earnings
-
Huge quake off Russia sparks Pacific tsunami warnings
BTI | 0.08% | 52.81 | $ | |
BCC | -0.05% | 86.09 | $ | |
GSK | 2.66% | 38.7 | $ | |
RIO | -2.14% | 60.965 | $ | |
CMSC | 0.49% | 22.61 | $ | |
BP | -2.03% | 32.305 | $ | |
JRI | -0.46% | 13 | $ | |
RELX | -0.14% | 51.85 | $ | |
NGG | -0.58% | 70.115 | $ | |
BCE | -1.32% | 23.52 | $ | |
SCU | 0% | 12.72 | $ | |
RYCEF | 2.59% | 13.5 | $ | |
VOD | -0.5% | 11.055 | $ | |
CMSD | 0.82% | 23.09 | $ | |
RBGPF | -4.75% | 74.03 | $ | |
SCS | 0% | 10.51 | $ | |
AZN | 2.36% | 75.77 | $ |

High times for German cannabis firm amid medical boom
At an undisclosed site in Germany's Bavaria state, pharmaceutical CEO Philip Schetter opens a 75-centimetre (30-inch) thick steel door that secures his wares: vast amounts of cannabis.
"Better safe than sorry," he says during a visit to the compound run by Cantourage, a producer and distributor of cannabis-based medicinal products.
Marijuana has been partially legalised in Germany, but the firm fears its wares from as far as Jamaica, Uganda and New Zealand could make it an attractive target for criminals.
"We are committed to the highest safety standards -- for our employees as well as for our products," Schetter told AFP.
Inside the facility, staff wearing surgical gowns, hairnets and face masks were busy using small scissors to cut up dried cannabis flowers.
The brownish-green buds are used to relieve chronic pain and sleep disorders, treat certain forms of epilepsy and offer support for cancer, HIV and palliative care patients.
Medical cannabis has been a boon for the Berlin-based company whose website slogan says "we love cannabis" and whose Frankfurt Stock Exchange ticker symbol is "HIGH".
Last year it booked revenue of 51.4 million euros, a 118 percent increase on 2023.
The company with 70 staff says it allows producers to enter the European medical cannabis market by processing and distributing their dried flowers and extracts.
Competitors include the Netherlands' Bedrocan and Canada's Aurora, which also grows cannabis.
In Germany, the pungent green plant has been available with a prescription since 2017.
One benefit of laboratory-tested and certified medical cannabis is clarity about its origin, processing path and active ingredient content, said Schetter.
"If I went to the black market, the choice would be rather limited and I would be given anything, without knowing what it contains," he said. "And often the product is contaminated. You may even doubt that it is cannabis."
- 'Frosted Cookies' -
Cantourage markets its medicines in eye-catching ways, naming them after their cannabis strains.
Among its products are "Frosted Cookies", "Lemon Berry Candy" and "Chemdawg", complete with colourful stickers that help build brand loyalty even if they do not appear on the packaging.
"Classical pharma firms do classical pharma marketing," Schetter said. "We're just young and creative," he added, noting that the boundaries between recreational and medicinal drugs are sometimes "blurred".
"You can argue about when a product is recreational and when it is medicinal," he said. "Cannabis helps in the treatment of certain symptoms."
Most European nations have legalised medicinal cannabis in some form, but Germany has more liberal rules than most.
The former centre-left government last year made it easier to get cannabis on prescription. It also legalised possession of up to 25 grams for personal, non-medical use and allowed households to grow up to three marijuana plants.
"The change in the law meant lots of people became aware for the first time that you can get cannabis from the chemist without being gravely ill," Schetter said. "That led to a surge in demand."
Pharmacies filled over 1,000 percent more cannabis prescriptions in December 2024 than they did the previous March, before the law was loosened, according to Bloomwell, an online platform that puts patients in touch with doctors for cannabis treatment.
- 'Shame for country' -
The legal change did not put everyone in high spirits, least of all Germany's conservative new Chancellor Friedrich Merz, who during the election campaign demanded the legalisation be reversed.
His ally, Bavarian premier Markus Soeder, last year charged that the loosening of the law was a "shame for the country" and vowed his state would apply the law "as strictly as possible".
Since Merz agreed to share power with the centre-left Social Democrats, his coalition government has taken a softer line, pledging only an "open-ended evaluation" of the issue.
Schetter said he was relaxed about the pending review, telling AFP that "we're curious to see what comes out of this".
He acknowledged that "regulatory risk does come up as a topic from time to time" in his talks with investors.
But even a reversal of the latest change to the law should leave Cantourage's business model intact, Schetter said.
"We are a pharmaceutical company. We make medicines and deliver them to chemists."
He even dared to dream that the review could go the other way, meaning "further steps will be taken to turn partial legalisation into full legalisation".
W.Morales--AT